Join McCreadie Group at Research Revolution 2026 to connect with our team, learn more about Vestigo®, and hear from our President, Sara Brueck Nichols.
Clinical trial start-up is still running on spreadsheets, email chains, and crossed fingers, and timelines are slipping as a result.
Join Sara Brueck Nichols, President of McCreadie Group, and fellow industry leaders for the panel: Study Start-Up Reimagined: Killing the Startup Bottleneck.
This panel will explore how modern trial teams are moving away from slow, serial start-up processes in favor of connected workflows, parallel execution, real-time operational visibility, and AI-enabled coordination.
Sara joined McCreadie Group in 2024 from Optum Rx, a UnitedHealth Group company. She is responsible for driving growth, product, and service strategy, and comes with nearly 25 years of experience in strategic planning, operational optimization, and data-driven decision making. For the last 8.5 years, she has focused on the intersection of marketing, operations, and technology in the pharmacy services space: including data and analytics, scalability, efficiency, transformation, and privacy. Sara holds a Master of Healthcare Administration from the University of Utah’s Eccles School of Business.
Vestigo® is a site enablement platform designed to help research sites and clinical trial pharmacies digitize and standardize IMP workflows.
Purpose-built for IMP operations, Vestigo® helps reduce manual burden and human error while supporting consistent, audit-ready processes.
Linking you to the latest in research pharmacy and IDS best practices